[1] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[2] |
CHEN Junyao, ZHANG Wentao, LIU Qiao, NIE Jianyun.
Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly
[J]. China Oncology, 2023, 33(5): 506-516.
|
[3] |
SHAO Zhibo, YANG Benlong, WU Jiong.
Progress of important clinical trials of breast cancer in China in 2022
[J]. China Oncology, 2023, 33(2): 103-109.
|
[4] |
GUO Qing, ZHANG Jian.
Advances in targeted therapy for HER2-low breast cancer
[J]. China Oncology, 2023, 33(2): 181-190.
|
[5] |
ZHANG Xiaowei, LIU Xin, LUO Zhiguo.
Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO
[J]. China Oncology, 2023, 33(11): 989-992.
|
[6] |
XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin.
New research advances and future prospect in precision treatment of triple-negative breast cancer
[J]. China Oncology, 2022, 32(8): 669-679.
|
[7] |
GONG Chao , CHEN Kui , ZHANG Dekun , XIE Jingfeng , WU Fanghua , HUANG Yudian , XUE Yuqin , WANG Liqun .
Construction of a prediction model for metastasis in gastric cancer based on the weighted gene co-expression network analysis
[J]. China Oncology, 2021, 31(8): 746-753.
|
[8] |
LIU Bin , ZHENG Pengyuan , MI Yang , REN Feifei , GAO Shuang , LIU Chuan , LI Fazhan .
Expression of LRP8 in gastric cancer and its significance in tumorigenesis
[J]. China Oncology, 2021, 31(4): 285-293.
|
[9] |
HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang .
Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer
[J]. China Oncology, 2021, 31(3): 221-226.
|
[10] |
CHEN Yang , LIU Wei , LI Ruimin , WANG Qifeng , SHEN Xigang , TANG Wei .
Radiogenomics: association between BI-RADS mammographic imaging features and the 21-gene recurrence score
[J]. China Oncology, 2020, 30(7): 505-511.
|
[11] |
JIANG Mengyi , LU Yanqiao , WANG Hongxia .
Research progress and clinical significance of breast cancer heterogeneity
[J]. China Oncology, 2020, 30(5): 394-400.
|
[12] |
SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng .
Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer
[J]. China Oncology, 2020, 30(3): 186-191.
|
[13] |
CAO Xiaoshan, CONG Binbin.
The progress of treatment for triple-negative breast cancer in the era of precision medicine
[J]. China Oncology, 2019, 29(12): 971-976.
|
[14] |
ZHENG Xiaying, CHEN Junxia.
Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation
[J]. China Oncology, 2019, 29(11): 845-854.
|
[15] |
ZHU Xiuzhi, CHEN Li, JI Lei, GAO Yu, WANG Zhonghua.
Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors
[J]. China Oncology, 2019, 29(11): 899-905.
|